El cuerpo humano es una maravilla de la complejidad, y a veces, nos sorprende con síndromes y condiciones médicas extraordinarias y poco comunes. En este artículo, nos adentraremos en el mundo de lo inusual y exploraremos los 5 síndromes más extraños conocid …
Los 5 síndromes más extraños: Explorando las rarezas de la condición humana Read More »
En el vasto universo de la física y la termodinámica, una ley fundamental emerge para explicar cómo el orden y el caos interactúan en todos los rincones del cosmos. Nos referimos a la ley de la entropía, un concepto fascinante que abarca desde el nivel subató …
Descifrando el enigma de la entropía: La ley que rige el orden y el caos en el universo Read More »
Gilead Sciences, Inc. announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® for the treatment of adults with chronic hepatitis delta infection.
En el vasto y microscópico mundo bacteriano, existen formas de vida sorprendentes que desafían nuestra comprensión de la vida en su escala más diminuta. En esta ocasión, nos adentraremos en el reino de la microbiología para descubrir a la bacteria más …
restor3d, Inc. and Conformis, Inc. announced that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approximate 96 percent premium to the closing price of Conformis stock on
SK pharmteco, SK Inc.’s contract development manufacturing organization for pharmaceuticals, successfully completed its second facility for Cell and Gene Therapies manufacturing in Europe.
SK pharmteco doubles viral vector production capacity in Europe Read More »
RELIEF THERAPEUTICS Holding SA and the World Orphan Drug Alliance announced an exclusive, long-term distribution agreement between Relief Therapeutics’ subsidiary APR Applied Pharma Research SA and WODA’s member company Vector Pharma FZCO to introduce PKU GOLIKE Plus®3-16 in the Middle East.
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, announced the closing of the previously announced private placement.
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement Read More »
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd. for rare diseases within the contractually agreed time frame.
It’s the second time the bill has been reintroduced in Congress as proponents of virtual care look to solidify COVID-19 gains in telehealth accessibility and use before temporary flexibilities run out at the end of 2024.
Telehealth groups applaud CONNECT reintroduction in Senate Read More »
